Abstract: A method for securing the movement of virtual machines (VMs) between hosts. The method includes obtaining a first VM movement request; in response to obtaining the first VM movement request, identifying a first VM of the VMs and a first targeted host of the hosts associated with the first VM movement request using VM metadata and host metadata; making a first determination that the first targeted host is registered; in response to making the first determination, initiating the movement of the first VM to the first targeted host; and initiating, after the movement of the first VM, encryption of communication between the first VM and the first targeted host.

Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.

Abstract: A method for securing the movement of virtual machines (VMs) between hosts. The method includes obtaining a first VM movement request; in response to obtaining the first VM movement request, identifying a first VM of the VMs and a first targeted host of the hosts associated with the first VM movement request using VM metadata and host metadata; making a first determination that the first targeted host is registered; in response to making the first determination, initiating the movement of the first VM to the first targeted host; and initiating, after the movement of the first VM, encryption of communication between the first VM and the first targeted host.

Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.

Abstract: The present invention relates to compositions and methods for binding and detecting or measuring renalase. In one embodiment, the renalase binding molecule measures renalase amount or activity. Thus, in diseases and conditions where a measurement of renalase is beneficial, such renalase binding molecules may act as diagnostics.

Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.

Abstract: The invention relates to a chromatography column assembly that offers an affordable self-packed column for performing chromatographic separation. The chromatography column assembly comprises a column tube having a first and a second opening at substantially opposite ends, and an end cap of either a snap fit design or a bolted design. The column assembly may further include an adaptor shaft inserted into the column through the end cap for achieving a desired bed volume. The column assembly may also include a second end cap enclosing the second opening, and an optional adaptor shaft may be inserted into the column through the second end cap, enabling further adjustment of the bed volume.

Abstract: The invention relates to a chromatography column assembly that offers an affordable self-packed column for performing chromatographic separation. The chromatography column assembly comprises a column tube having a first and a second opening at substantially opposite ends, and an end cap of either a snap fit design or a bolted design. The column assembly may further include an adaptor shaft inserted into the column through the end cap for achieving a desired bed volume. The column assembly may also include a second end cap enclosing the second opening, and an optional adaptor shaft may be inserted into the column through the second end cap, enabling further adjustment of the bed volume.

Abstract: Assays using binding studies involving function of BRCA1a protein have use for diagnosis and for evaluation of possible tumorogenicity of agents, particularly estrogenic agents. The assays do not rely on use of a probe for only specific sequences, but on effects of known and unknown or not previously studied sequences (consequence of genetic changes) or posttranslational modification of BRCA1 proteins (as a consequence of epigenetic changes) as seen in hereditary and sporadic cancers.

Abstract: The present invention claims fluoro- & iodo-containing aldehydes as ALDH substrates for use as diagnostic imaging agents or as therapeutic agents. The aldehydes are both directly and indirectly attached to an aromatic or a straight chain ring. ALDH activity was monitored either by the formation of acid-product or consumption of aldehyde substrates.

Abstract: Assays using binding studies involving function of BRCA1a protein have use for diagnosis and for evaluation of possible tumorogenicity of agents, particularly estrogenic agents. The assays do not rely on use of a probe for only specific sequences, but on effects of known and unknown or not previously studied sequences (consequence of genetic changes) or posttranslational modification of BRCA1 proteins (as a consequence of epigenetic changes) as seen in hereditary and sporadic cancers.